prr very recent news article from leipzig

The very recent news article extract below concerns Prima Biomed in Europeand the upcoming phase 3 trials ( and has been translated literally from German to English)


worth a read - especially the following statement:

"The study is a globally recognized leading project and one of our biggest projects," says the 43-year-old biochemist Schmiedeknecht.

cheers
Birdseye



Tuesday 20 September 2011
(S?chsische Zeitung)


Fight against early death
By Sven Heitkamp


The death rate from ovarian cancer is high. Leipzig researchers and an Australian company to stop the disease. With blood cells.

The diagnosis is often a shock: Many women who develop ovarian cancer have sometimes only a few years left to live. The death rate is the highest among the gynecological cancers. The malignant tumors are the medicine has hardly beatable.

Researchers at the Leipzig Fraunhofer Institute for Cell Therapy and Immunology (IZI) Start now but for the Australian biotechnology company Prima BioMed Europe-wide study on a new drug to improve the chances of recovery for women and alleviate their suffering.

The idea of scientists is simple and complicated: women victims, says Project Manager Gerno Schmiedeknecht, after surgery and before chemotherapy, --white blood cells are removed. These are loaded in the clean room of the Fraunhofer Institute,--The protein associated with the immune cells are injected back to the women.

The body responds with defenses, the immune system looks for other tumor cells and eliminate them. --.


Whether the new treatment works in practice, Prima BioMed went along with the "IZI" now proven in an extensive study with 800-1000 subjects in Europe, the USA and Australia. "The first run through levels of security.

Now it is all about the effectiveness of this cell therapy, "says Schmiedeknecht. In exchange, one half of the participating patients ineffective placebos and the other group the new drug.

For the study, the blood cells of affected women from all over Europe to Leipzig will be flown in a laboratory at the Leipzig Institute modified and brought back to the patients. Preparations are underway for the start of 2012 to begin the clinical study.

2014 is the earliest to expect results.


"The study is a globally recognized leading project and one of our biggest projects," says the 43-year-old biochemist Schmiedeknecht.

---. If they are ultimately successful, they will apply for Prima BioMed Europe-wide approval for new therapies.


Saxony supports research projects with more than four million euros. The project is an example for the region and they hope, says Science Minister Sabine Schorlemer of (independent), that there is an incentive for further biotechnological developments in Leipzig.


The economic benefits can be seen now: Prima BioMed has already settled with a German subsidiary in Leipzig.-----

source; http://www.sz-online.de/nachrichten/artikel.asp?id=2867419